Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-371 inhalation solution with and without oral ivacaftor in primary ciliary dyskinesia
2015-004917-26Phase 2Completed
- Sponsor
- Parion Sciences
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary ciliary dyskinesia (PCD) comparing VX-371 inhalation alone, VX-371 inhalation plus oral ivacaftor and Placebo/control (3 arms). Primary endpoint: Primary endpoints Part A. Started May 2016; status: completed.
02
Drugs
idrevlorideivacaftor
03
Conditions
primary ciliary dyskinesia (PCD)
Beyond the preview
Go deeper on 2015-004917-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004917-26.